Get the Daily Brief
Latest Biotech News
Congress clears Medicare path for FDA‑approved MCED tests — coverage set
Congress approved an appropriations bill that includes a provision allowing Medicare coverage for FDA-approved multi-cancer early detection (MCED) tests, setting reimbursement equal to current...
AI in drug discovery and lab automation — Insilico selects candidate; Phylo raises seed
Insilico Medicine nominated ISM5059, a peripheral‑restricted NLRP3 inhibitor, as a preclinical candidate developed with generative AI, while Phylo raised $13.5 million to commercialize Biomni Lab,...
Next‑gen immune therapies advance — exhaustion reversal and safer IL‑12 variants
Preclinical work disclosed a first‑in‑class fusion protein able to reverse T‑cell exhaustion across multiple tumor models, while an alternative next‑generation IL‑12 program (STK‑026) surfaced...
CIRM commits $100M to platform gene‑therapy program for rare diseases
The California Institute for Regenerative Medicine (CIRM) launched the RAPID initiative, allocating $100 million over two years to support platform-based in vivo genetic therapies for rare...
Eikon Upsizes IPO to $381M — Biotech Lists with Cancer R&D War Chest
Eikon Therapeutics completed an upsized $381 million initial public offering, selling 21.2 million shares at $18 apiece to fund clinical development of its oncology pipeline. The California...
Veradermics Prices $256M IPO — Oral Rogaine Advances to Pivotal Trials
Veradermics priced an upsized $256.3 million IPO to finance pivotal phase II/III studies of VDPHL‑01, an oral formulation of minoxidil developed to avoid cardiovascular risks of prior systemic...
Pfizer’s Metsera GLP‑1 Posts Positive Data — Market Reaction Mixed
Pfizer released midstage data for PF‑08653944, the once‑monthly GLP‑1 acquired in its $10B Metsera deal, reporting placebo‑adjusted weight loss up to ~12.3% in one cohort and up to ~10.5% at six...
Congress Reauthorizes Pediatric PRV — Industry Wins; PBM Reforms Included
Congress extended the rare pediatric priority review voucher (PPRV/PRV) program through 2029 as part of a broader spending package that also included pharmacy benefit manager (PBM) transparency...
FDA Asks Amgen to Withdraw Tavneos — Amgen Declines, Regulatory Fight Looms
The FDA has asked Amgen to withdraw Tavneos (avacopan) from the US market while revisiting data‑adjudication issues from the drug’s pivotal trial; Amgen has publicly refused and said it will...
BARDA Launches $100M Antiviral Prize — Norovirus Culture Breakthrough Follows
BARDA unveiled the first stage of a $100 million prize competition to spur broad‑spectrum small‑molecule antivirals against Togaviridae and Flaviviridae, aiming to accelerate preclinical and...
Wearable Drug‑Monitoring Patch Validated in Pilot — Continuous TDM Enters Clinic
A pilot clinical trial published in Nature Biotechnology demonstrated a wearable, electrochemical aptamer‑based patch that continuously measures drug concentrations from interstitial fluid in...
AI Meets Regenerative Medicine — Foundation Models and Phylo’s $13.5M Seed
Researchers and startups are applying foundation models to reduce variability in stem‑cell derived therapeutics while investors back AI‑native lab platforms. An AI foundation model targeting...
Platform Strategy for Rare Genetic Therapies: CIRM $100M RAPID and PrimeGen SPAC Move
The California Institute for Regenerative Medicine approved a $100 million RAPID program to fund platform‑based in‑vivo genetic therapies for rare diseases, shifting from single‑asset funding...
Genetic and Cellular Routes to Stronger Immunotherapy — New T‑cell and NKT Findings
A Nature study identified two genes that govern CD8+ T‑cell fate and suggest levers to boost killer T‑cell durability and function in cancer, while UCLA researchers reported an engineered...
Eikon Therapeutics Prices $381M IPO: Mapping Proteins to Markets
Eikon Therapeutics sold 21+ million shares at $18 apiece to secure $381 million in an initial public offering, marking one of the largest biotech listings this week. The San Francisco–area company...
Veradermics Upsizes IPO to $256M: Oral Minoxidil Trials Funded
Veradermics priced an upsized initial public offering that raised roughly $256 million to fund three pivotal trials of VDPHL‑01, an oral formulation of minoxidil for pattern hair loss. The company...
Pfizer’s Monthly GLP‑1 Data: Modest Weight Loss, Bigger Phase III Plan
Pfizer released Phase II data for PF‑08653944 (formerly Metsera’s candidate) showing placebo‑adjusted weight loss up to ~12.3% at 28 weeks and up to 10.5% in an alternative analysis — outcomes the...
Phylo Raises $13.5M Seed: Agentic AI for Lab Workflows
Phylo closed a $13.5 million seed round to launch Biomni Lab, an AI‑native integrated biology environment that embeds agentic AI into lab workflows for planning, execution and collaboration. The...
FDA Asks for Tavneos Withdrawal — Amgen Refuses: Regulation in the Hot Seat
The U.S. Food and Drug Administration has asked Amgen to withdraw Tavneos (avacopan) following scrutiny of old trial re‑adjudication practices and concerns over benefit‑risk signals; Amgen has...
BARDA/HHS Pledge $100M Prize for Broad‑Spectrum Antivirals
BARDA (via HHS) launched a $100 million prize competition to accelerate development of broad‑spectrum small‑molecule antivirals targeting Togaviridae and Flaviviridae families. The multi‑stage...